利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.037 秒)

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    3.
    发明授权
    Sustained release intraocular implants and methods for preventing retinal dysfunction 有权
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US08293210B2

    公开(公告)日：2012-10-23

    申请号：US11927615

    申请日：2007-10-29

    申请人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    发明人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    IPC分类号： A61K31/498 ,  A61P27/16

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

    摘要翻译： 生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以防止发生一种或多种眼部病症，或者减少眼部疾病如眼睛神经感觉障碍等的一种或多种症状。

    Sustained release intraocular implants and methods for preventing retinal dysfunction
    4.
    发明申请
    Sustained release intraocular implants and methods for preventing retinal dysfunction 审中-公开
    持续释放眼内植入物和预防视网膜功能障碍的方法

    公开(公告)号：US20110251201A1

    公开(公告)日：2011-10-13

    申请号：US13154079

    申请日：2011-06-06

    申请人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    发明人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    IPC分类号： A61K31/498 ,  A61P27/02

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

    摘要翻译： 生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以防止发生一种或多种眼部病症，或者减少眼部疾病如眼睛神经感觉障碍等的一种或多种症状。

    SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION
    6.
    发明申请
    SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION 有权
    可持续释放内镜植入物和预防后遗症的方法

    公开(公告)号：US20080131372A1

    公开(公告)日：2008-06-05

    申请号：US11927615

    申请日：2007-10-29

    申请人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    发明人： Glenn T. Huang ,  James Burke ,  Patrick M. Hughes ,  Kai-Ming Zhang ,  Ton Lin ,  Larry A. Wheeler ,  Rosy Sheng Donn

    IPC分类号： A61K31/498 ,  A61P27/16

    CPC分类号： A61K31/498 ,  A61K9/0051 ,  A61K47/34

    摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

    摘要翻译： 生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。 植入物可以放置在眼睛中以防止发生一种或多种眼部病症，或者减少眼部疾病如眼睛神经感觉障碍等的一种或多种症状。

    Sustained release intraocular implants and related methods
    8.
    发明授权
    Sustained release intraocular implants and related methods 有权
    持续释放眼内植入物及相关方法

    公开(公告)号：US08962009B2

    公开(公告)日：2015-02-24

    申请号：US13840535

    申请日：2013-03-15

    申请人： Glenn T. Huang ,  Thierry Nivaggioli

    发明人： Glenn T. Huang ,  Thierry Nivaggioli

    IPC分类号： A61F2/14 ,  A61K9/00 ,  A61K31/573 ,  A61K45/06 ,  A61K31/58

    CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

    摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

    摘要翻译： 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。

    Sustained release intraocular implants and related methods
    9.
    发明授权
    Sustained release intraocular implants and related methods 有权

    公开(公告)号：US08440216B2

    公开(公告)日：2013-05-14

    申请号：US13613636

    申请日：2012-09-13

    申请人： Glenn T. Huang ,  Thierry Nivaggioli

    发明人： Glenn T. Huang ,  Thierry Nivaggioli

    IPC分类号： A61F2/14

    CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

    摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

    Sustained release intraocular implants and related methods
    10.
    发明申请
    Sustained release intraocular implants and related methods 有权

    公开(公告)号：US20130236525A1

    公开(公告)日：2013-09-12

    申请号：US13840535

    申请日：2013-03-15

    申请人： Glenn T. Huang ,  Thierry Nivaggioli

    发明人： Glenn T. Huang ,  Thierry Nivaggioli

    IPC分类号： A61K9/00 ,  A61K31/58

    CPC分类号： A61K9/0051 ,  A61K9/0092 ,  A61K31/573 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

    摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.